Doctor of Osteopathy Program year 2021 Reported 2019–2021 Source: CMS Open Payments, 2026 publication

Timothy McCay

Diagnostic Radiology Tulsa, OK Doctor of Osteopathy

NPI 1245221761 CMS profile 540809

744 W 9Th St, Tulsa, OK 74127

Open in the dashboard

General payments

$678

40 records reported · program years 2019–2021

Research payments

$0

Paid to them · None reported · program years 2019–2021

Ownership & investment interest

$0

None reported

Through program year 2021, Timothy McCay of Tulsa, OK is reported in the CMS Open Payments database as having received $678 across 40 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Diagnostic Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2021 General $60 4
2020 General $273 15
2019 General $345 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Timothy McCay
  • Diagnostic Radiology median
  • Middle half of Diagnostic Radiology
  • National median

In program year 2025, general payments to Timothy McCay were reported at $0. Among 8,325 Diagnostic Radiology profiles paid that year, the median was $112 and the middle half received between $32 and $349.

Show as a table
Year Timothy McCay Diagnostic Radiology median Middle half National median
2019 $345 $108 $29–$318 $163
2020 $273 $65 $21–$252 $114
2021 $60 $92 $24–$292 $132
2022 $0 $104 $29–$294 $149
2023 $0 $110 $29–$337 $160
2024 $0 $113 $30–$356 $164
2025 $0 $112 $32–$349 $169

Breakdown

Who paid General payments · program years 2019–2021
  1. AstraZeneca Pharmaceuticals LP $96 7 payments
  2. Lilly USA, LLC $94 5 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $93 5 payments
  4. Ipsen Biopharmaceuticals, Inc $51 2 payments
  5. Curium US LLC $46 2 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $40 2 payments
  7. Genzyme Corporation $36 2 payments
  8. Seattle Genetics, Inc. $33 2 payments
  9. Novartis Pharmaceuticals Corporation $30 2 payments
  10. Puma Biotechnology, Inc. $27 2 payments
  11. Other $131 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2021
  1. Food and Beverage $678 40 payments
Products named General payments · program years 2019–2021
  1. VERZENIO $94 5 payments
  2. CYRAMZA $94 5 payments
  3. ALIMTA $56 3 payments
  4. Nubeqa $55 3 payments
  5. Xofigo $55 3 payments
  6. ONIVYDE $51 2 payments
  7. SOMATULINE DEPOT $51 2 payments
  8. CALQUENCE $41 3 payments
  9. Stivarga $37 2 payments
  10. GAUCHER-DISEASE $36 2 payments
  11. Other $328 23 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 161 billing codes

Paid by Medicare

$148,755

Medicare's payments for the services billed

Medicare patients

3,184

Average age 74

Services billed

4,752

1,843 women, 1,341 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Ischemic heart disease 42%
Diabetes 41%
Chronic kidney disease 35%
COPD 33%
Heart failure 32%
Depression 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

40 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Diagnostic Radiology in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record